The wet age-related macular degeneration (AMD) market in the United States is replete with intravitreal (IVT) therapies—including Regeneron’s Eylea, Roche / Genentech’s Lucentis and Vabysmo, Biogen’s Byooviz, Coherus’s Cimerli, and Novartis’s Beovu. Although IVT agents drive favorable outcomes for most patients, they require chronic injections that limit persistency and compliance and prevent long-term achievement of an optimal response. Gene therapy for wet AMD is on the horizon, bringing the potential to reduce IVT injections and improve outcomes for patients, although questions remain about the profiles of the most eligible candidates for these innovative therapeutic options. The market for IVT therapies to treat advanced dry AMD with geographic atrophy (GA) is far less developed, but gene therapy is also advancing in the pipeline. This report addresses key questions regarding ophthalmologists’ willingness to prescribe emerging gene therapies in both forms of AMD and key drivers of their prescribing, their preferences regarding differentiating clinical attributes, and through conjoint analysis, the clinical attributes they prioritize when selecting optimal wet AMD gene therapy candidates.
Geography: United States
Primary Research: Survey of 101 U.S. ophthalmologists / retinal specialists in October 2023
Key agents covered: ABBV-RGX-314, ixo-vec (ADVM-022), 4D-150, JNJ-1887 (HMR59)
Clarivate’s Special Topics reports assess key trends in dynamic disease areas. This report on gene therapies in ophthalmology will help drug marketers and developers gain needed insight into treatment dynamics for IVT options in wet AMD and GA, HCPs’ desired achievements for emerging therapies, and physicians’ willingness to prescribe key emerging gene therapies; it also provides a conjoint analysis of clinical attributes that render a wet AMD patient to be an optimal candidate to receive a future gene therapy.